Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59,966 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.
Cheng Y, Fan Y, Liu X, Liu Y, Liu J, Wang D, Yu Y, Qin S, Liu W, Huang C, Zhang H, Liang J, Shi J, Sheng L, Yu H. Cheng Y, et al. Among authors: liu j, liu y, liu x, liu w. Oncol Lett. 2019 May;17(5):4701-4709. doi: 10.3892/ol.2019.10125. Epub 2019 Mar 8. Oncol Lett. 2019. PMID: 30988825 Free PMC article.
Akt Inhibition Enhanced the Growth Inhibition Effects of Low-Dose Heavy-Ion Radiation via the PI3K/Akt/p53 Signaling Pathway in C6 Glioblastoma Cells.
Huang K, Zhao W, Wang X, Qiu Y, Liu Z, Chen R, Liu W, Liu B. Huang K, et al. Among authors: liu z, liu b, liu w. Front Oncol. 2021 Apr 1;11:649176. doi: 10.3389/fonc.2021.649176. eCollection 2021. Front Oncol. 2021. Retraction in: Front Oncol. 2023 May 25;13:1205993. doi: 10.3389/fonc.2023.1205993 PMID: 33869050 Free PMC article. Retracted.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
59,966 results
You have reached the last available page of results. Please see the User Guide for more information.